Prosecution Insights
Last updated: November 10, 2026

Enalare Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Enalare Therapeutics Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned across 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution path rather than distribution across multiple examination resources.

MCKOY, QUINCY ANDRE is the busiest examiner, with 1 pending matter. Because the pending work is concentrated with one examiner and one art unit, prosecution planning can center on the current examination record, the cited issues, and the response strategy for that single matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MCKOY, QUINCY ANDRE 1 68.4% +41.0%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18213451 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY MCKOY, QUINCY ANDRE 28d

Top Art Units

Art UnitApps
1626 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18213451 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY MCKOY, QUINCY ANDRE 1626 §103 Final Rejection 28d Pending Jun 23, 2023

Managing Enalare Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Enalare Therapeutics Inc. have?

Enalare Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Enalare Therapeutics Inc. applications?

Quincy Andre Mckoy has the most, with 1 of Enalare Therapeutics Inc.'s pending office actions.

What technology area are Enalare Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month